CanFite Biopharma (CANF)
(Delayed Data from AMEX)
$2.04 USD
-0.01 (-0.49%)
Updated May 16, 2024 11:51 AM ET
3-Hold of 5 3
B Value F Growth A Momentum C VGM
Brokerage Reports
Can-Fite Biopharma Ltd [CANF]
Reports for Purchase
Showing records 181 - 200 ( 216 total )
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
3Q14 Results; CF101 Upcoming Catalysts and Expansion Potential
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Cant ''Fite'' a Potential Blockbuster in the Making; Initiating with Buy Rating
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: BENJAMIN R
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Major U.S. Visibility Shortly; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Healthcare - End of 2014 Biotech Highlights: Partnering Watch & Major Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
2Q14 Results; Topline Psoriasis Data Coming 1Q15; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Driving CF101 Profile and Targeting; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
CF102 Compassionate Use Approval for Liver Cancer Patient; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
Psoriasis Visibility and Important Background Activities for CF101
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
OphthaliX Updates On CF101 Eye Diseases Studies
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
1Q14 Results; Busy Year for Data Catalysts, Starting 2Q; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Can-Fite Biopharma Ltd
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.